《Genet法說筆記》中天集團旗下永笙-KY(4178)12月5日登錄興櫃承銷價為45元 持續追蹤異體臍帶血治療長新冠臨床二期和腦中風一期詳細數據
FDA: REGENECYTE建議配對六種 HLA-A 抗原、HLA-B 抗原和 HLA-DRB1 等位基因中的至少四種。REGENECYTE, HPC (Hematopoietic Progenitor Cell), Cord Blood, is an allogeneic cord bloodhematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoieticprogenitor cell transplantation procedures in conjunction with an appropriate preparative regimen
for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment。(https://www.fda.gov/media/183744/download?attachment)
.jpg)
